CLASS II Device recall · Reported 6 Apr 2016 · FDA Enforcement Report

Estradiol III recalled by Roche Diagnostics Operations

Roche Diagnostics Operations is recalling Estradiol III, distributed nationwide in the US. The recall was initiated on 7 Mar 2016 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesElecsys Estradiol III: 06656021190; all lot numbers are affected.
Quantity recalled23,630

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-1276-2016
FDA event ID
73411
Recalling firm
Roche Diagnostics Operations, Indianapolis, IN
Classification
Class II
Status
Terminated
Recall initiated
7 Mar 2016
FDA classified
31 Mar 2016
Reported
6 Apr 2016
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Particulate Matter

Timeline

7 Mar 2016Recall initiated by company
31 Mar 2016Classified by FDA+24 days
6 Apr 2016Published in enforcement report+6 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Due to the risk of a recently identified cross reactivity, the Elecsys Estradiol assay should not be used when monitoring patient being treated with fulvestrant. Customers should be informed that fulvestrant will increase the apparent concentration of estradiol in women being treated with this drug. If treatment with fulvestrant has been altered or discontinued as a result of falsely elevated e

Product as listed by the FDA

Estradiol III; Elecsys and cobas e analyzers; REF 06656021 190; M 6.5 mL, R1 9 mL, R2 9 mL, For USA: CONTENT M Streptavidin-coated microparticles 0.72 mg/ml; R1 Two biotinylated monoclonal anti-estradiol antibodies (rabbit) 2.5 ng/m and 4.5 ng/mL Mesterolone 130 ng/mL; R2 Estradiol derivative, labeled with ruthenium complex 4.5 ng/mL; Rx only Product Usage: Immunoassay for the in vitro quantitative determination of estradiol in human serum and plasma. The electrochemiluminescence immunoassay ECLIA is intended for use on Elecsys and cobas e immunoassay analyzers.

Where it was distributed

US Nationwide Distribution including Puerto Rico.

Nationwide Puerto Rico

Questions about this recall

Is Estradiol III recalled?

Yes. Roche Diagnostics Operations recalled Estradiol III on 7 Mar 2016. The recall is Class II and its status is Terminated. Recall number Z-1276-2016.

Why was it recalled?

Due to the risk of a recently identified cross reactivity, the Elecsys Estradiol assay should not be used when monitoring patient being treated with fulvestrant. Customers should be informed that fulvestrant will increase the apparent concentration of estradiol in women being treated with this drug. If treatment with fulvestrant has been altered or discontinued as a result of falsely elevated e

Which lots are affected?

Elecsys Estradiol III: 06656021190; all lot numbers are affected.

Where was it sold?

US Nationwide Distribution including Puerto Rico.

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Roche Diagnostics Operations

All 127

Other Test Kits & Diagnostics recalls

All 2,656